Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $50.
January 22, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer reaffirmed an Overweight rating on BridgeBio Pharma with a steady price target of $50.
The reiteration of an Overweight rating by a reputable analyst like Josh Schimmer suggests a positive outlook on the stock, which could instill confidence in investors and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100